Coherus BioSciences, Inc. (CHRS)
Pre-market:
| Previous close | 2.1800 |
| Open | 2.1500 |
| Bid | 2.1200 x 100 |
| Ask | 2.1800 x 1200 |
| Day's range | 2.1200 - 2.2200 |
| 52-week range | 1.4300 - 5.6300 |
| Volume | |
| Avg. volume | 2,273,167 |
| Market cap | 248.955M |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2024 and recent business highlights: RECENT BUSI
- GlobeNewswire
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
– New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining $75 million of its Pharmakon Advisors term loan. This further reduces the Compa
- GlobeNewswire
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-res
